How is the Lilly(Eli) & Co today?

The Lilly(Eli) & Co today is trading in the green, up by 2.09% at 737.67.

How has Lilly(Eli) & Co performed historically?

The Lilly(Eli) & Co is currently trading up 2.09% on an intraday basis in the past week the index rose 3.36%. The index has been down -18.50% in the past quarter and fell -9.50% in the past year. You can view this in the overview section.

What is Lilly(Eli) & Co Annual Revenue?

Lilly(Eli) & Co Annual Revenue rose 32%, in the last year to $45,042.7 M. Its sector's average revenue growth for the last fiscal year was 8.76%.

What is Lilly(Eli) & Co Annual Net Profit?

Lilly(Eli) & Co Annual Net Profit rose 102.08% in the last year to $10,590 M. Its sector's average net profit growth for the last fiscal year was -11.09%.

What is Lilly(Eli) & Co Price to Earning Ratio?

Lilly(Eli) & Co Price to Earning Ratio is 59.63, higher than its sector PE ratio of 4.35.

What is Lilly(Eli) & Co Stock Price?

Lilly(Eli) & Co Stock Price fell 9.5% and underperformed its sector by 64.97% in the past year.

What is Lilly(Eli) & Co Quarterly Revenue?

Lilly(Eli) & Co Quarterly Revenue rose 45.17% YoY to $12,728.5 M. Its sector's average revenue growth YoY for the quarter was 3.14%.

What is Lilly(Eli) & Co Quarterly Net profit?

Lilly(Eli) & Co Quarterly Net profit rose 23.02% YoY to $2,759.3 M. Its sector's average net profit growth YoY for the quarter was -212.88%.

What is Lilly(Eli) & Co Debt to Equity Ratio?

Lilly(Eli) & Co Debt to Equity Ratio of 2.37 is higher than 1. This implies that company assets are financed through debt.

What is Lilly(Eli) & Co Return on Equity(ROE)?

Lilly(Eli) & Co Return on Equity(ROE) for the last financial year was 84.84%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

What is Lilly(Eli) & Co Mutual Fund Holding?

Lilly(Eli) & Co Mutual Fund Holding increased by 1.48% in the last quarter to 62.34.

What is Lilly(Eli) & Co Interest Coverage Ratio?

Lilly(Eli) & Co Interest Coverage Ratio is 17.24, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

What is Lilly(Eli) & Co Institutional Holding?

Lilly(Eli) & Co Institutional Holding increased by 0.67% in the last quarter to 89.29.

Lilly(Eli) & Co XNYS: LLY

Lilly(Eli) & Co Live Share Price Today, Share Analysis and Chart

Name: Lilly(Eli) & Co: Is Infosys Ltd. worth buying?
Item: Lilly(Eli) & Co
Rating: 1.910805625
Author: Trendlyne DVM scores

Falling Comet

about

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumia...

737.67 15.10 (2.09%)

6.1M XNYS Volume

XNYS 30 May, 2025 5:30 PM (EDT)

Acquisition

Eli Lilly to acquire SiteOne Therapeutics for up to $1 bn, adding non-opioid pain drug to pipeline See details

High Financial Strength

55.6 / 100

Expensive Valuation

11.3 / 100

Technically Bearish

30.4 / 100

Falling Comet These stocks are with good financial quality. But, their bad valuation and technical aspects make the investor think before investing. View Similar Embed DVM

955

1Yr Price target upside is 30%

27 analysts

Lilly(Eli) & Co Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Lilly(Eli) & Co Live Share Price Today, Share Analysis and Chart

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumia...

SWOT Analysis

Lilly(Eli) & Co Live Price Chart

Lilly(Eli) & Co FAQ

How is Lilly(Eli) & Co today?

Lilly(Eli) & Co today is trading in the green, and is up by 2.09% at 737.67.

How has Lilly(Eli) & Co performed historically?

Lilly(Eli) & Co is currently trading up 2.09% on an intraday basis. In the past week the stock rose 3.36%. stock has been down -18.50% in the past quarter and fell -9.50% in the past year. You can view this in the overview section.